Haiwei Ma

Haiwei Ma

Auto-generated profile, based on publicly available information

Haiwei Ma


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2023 in International Immunopharmacology
Verified
Journal Article
Closed access
CXCong Xu
Cong Xu
SJShu-Qing Jin
Shu-Qing Jin
CJChen Jin
Chen Jin
ZDZi-Han Dai
Zi-Han Dai
YWYu-Hao Wu
Yu-Hao Wu
WFWen-Lai Fang
Wen-Lai Fang

4 October 2025 in Free Radical Biology and Medicine
Verified
Journal Article
Open access
KLKechi Li
Kechi Li
TYTao Yang
Tao Yang
FCFeiyu Chen
Feiyu Chen
CLChao Lou
Chao Lou
YCYanlin Chen
Yanlin Chen
HMHaiwei Ma
Haiwei Ma
Osteoarthritis, a common chronic degenerative disease in the field of orthopedics, is caused by the interaction of mechanical stress, traumatic inflammation, and metabolic imbalance, and this interaction progresses over time. MOTS-c, a mitochondria-derived peptide, exerts pivotal roles in regulating metabolism, anti-inflammation, and antioxidant stress responses. However, current research on the role of MOTS-c in osteoarthritis remains scarce, and its specific mechanism of action remains unclear. Therefore, this study aims to further explore the molecular mechanisms by which MOTS-c regulates osteoarthritis. Exogenous supplementation of MOTS-c improves mitochondrial dysfunction, inhibits the activation of inflammatory bodies and rescues chondrocyte pyroptosis, thereby regulating the metabolic balance of extracellular matrix (ECM). Mechanistically, MOTS-c plays a key role in LPS-induced oxidative stress and chondrocyte pyroptosis through the Nrf2/TXNIP/NLRP3 axis. Our research demonstrates that MOTS-c can not only effectively inhibit the expression of inflammatory factors but also promote the expression of major components of the extracellular matrix (ECM) and suppress the production of matrix metalloproteinases. We validated the in vivo efficacy of MOTS-c by establishing a murine osteoarthritis model. Analysis of imaging and histopathological results revealed that MOTS-c can effectively delay the degeneration of articular cartilage and ameliorate the progression of osteoarthritis. Collectively, our findings uncover the intrinsic regulatory mechanism of MOTS-c in chondrocytes and its potential value in the treatment of osteoarthritis.

17 September 2025 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
YLYahong Lu
Yahong Lu
YBYu Bai
Yu Bai
WLWeiqing Li
Weiqing Li
ZZZhiguo Zhou
Zhiguo Zhou
HLHeihuan Lai
Heihuan Lai
DHDengwei He
Dengwei He
Background: Sarcopenia is a systemic skeletal muscle disease that seriously affects the health of the aged population. Exercise prevents sarcopenia, but the underlying mechanobiological and metabolic mechanisms need to be further investigated. Methods: Carnitine and organic cation transporter 2 (OCTN2) levels were assessed in humans and animals with sarcopenia. Skeletal muscle function and histomorphology were assessed in an animal model. Mitochondrial structure and function were assessed via MitoSox and JC‐1 staining, seahorse assays and electron microscopy. Molecular mechanisms were assessed by Western blot analysis, qPCR, a luciferase reporter gene assay, chromatin immunoprecipitation and immunofluorescence in C2C12 myotubular cells. Results: A total of 66 patients were included in the study (Healthy group, % females: 44.74%, mean age: 67.40 ± 8.2, mean BMI: 24.7 ± 3.80 kg/m 2 ; Sarcopenia group, % females: 39.29%, mean age: 71 ± 8.42, mean BMI: 23.1 ± 2.98 kg/m 2 ). Serum carnitine levels decreased in sarcopenia patients (10 868 ± 3466 ng/mL vs. 8469 ± 2360 ng/mL, p < 0.01). Carnitine is an independent protective factor for sarcopenia (OR, 0.757; 95% CI 0.599–0.923, p = 0.0107). Carnitine and OCTN2 levels also decreased in the muscles of mice with dexamethasone‐induced muscle atrophy (carnitine: −16.5%, p < 0.05) and aged mice (carnitine: −32.03%, p < 0.01). Suppressed expression of OCTN2 led to a decrease in muscle carnitine (2983 ± 466.3 ng/mL vs. 2517 ± 355.3 ng/mL, p < 0.05), as well as muscle atrophy in mice. Swimming exercise enhanced mice carnitine‐dependent fatty acid oxidation and increased OCTN2 expression (OCTN2: +8.4%, p < 0.05). Knockdown of OCTN2 partially reduced this effect during swimming. Cellular experiments revealed that mechanical stimulation upregulated OCTN2 expression. OCTN2 knockdown impaired myotube formation and led to the disruption of the cellular mitochondrial structure. Further mechanistic studies showed that mechanical forces enhanced OCTN2 transcription and regulated carnitine metabolic homeostasis through the Yap/Tead4 pathway. Yap agonist XMU alleviated dexamethasone‐induced muscle atrophy (grip: +13%, p < 0.05; cross‐sectional area of the gastrocnemius muscle: +8%, p < 0.05). In a high‐fat diet mouse model and in cellular experiments, carnitine supplement improved mitochondrial structure and alleviated mitochondrial dysfunction by reducing excessive lipid accumulation and thus altered myocyte fate. Conclusion: Swimming and carnitine supplementation alleviated sarcopenia. The mechanism was closely related to the enhancement of OCTN2 expression after Yap activation and the enhancement of carnitine‐mediated lipid metabolism. These findings reveal exercise regulates skeletal muscle by coupling mechanics and metabolism synergetically. We provide a new therapeutic strategy for sarcopenia.

13 January 2026 in Free Radical Biology and Medicine
Verified
Journal Article
Open access
YCYitao Chen
Yitao Chen
JFJiawei Fang
Jiawei Fang
ZZZhiguo Zhou
Zhiguo Zhou
HMHaiwei Ma
Haiwei Ma
SLShijie Liu
Shijie Liu
DHDengwei He
Dengwei He
Osteoarthritis (OA), a common degenerative joint disorder, currently lacks effective therapeutic strategies to alleviate its progression. This study aims to investigate the function and underlying mechanisms of dihydrolipoic acid (DHLA) in inhibiting ferroptosis in chondrocytes and alleviating OA progression. Mouse primary chondrocytes were exposed to IL-1β to induce ferroptosis and treated with DHLA in vitro, followed by the assessment of ferroptosis-related markers and indicators of chondrocyte anabolism and catabolism. The underlying therapeutic mechanisms of DHLA in OA were further investigated through computer network analysis and experimental validation. The surgery destabilization of the medial meniscus was then conducted to establish the mouse OA model before treatment with DHLA. The therapeutic effect of DHLA in OA mice was evaluated through micro-CT and histological analyses. DHLA suppressed the IL-1β-induced increases in levels of intracellular reactive oxygen species, Fe2+, lipid peroxidation, and malondialdehyde in chondrocytes, while attenuating the depletion of glutathione, as well as the levels of GPX4 and SLC7A11. Furthermore, the IL-1β-induced reductions in proteoglycans secretion and the levels of Collagen II, Aggrecan, and SOX9 were attenuated by DHLA, while inhibiting the upregulation of MMP13, MMP3, and ADAMTS5. Further studies revealed that the downregulation of FOXO1 expression and the upregulation of TXNIP expression induced by IL-1β were ameliorated by DHLA. The protective effects of DHLA were abolished by AS1842856, a specific FOXO1 inhibitor, whereas this inhibition was reversed by SRI-37330, a specific TXNIP inhibitor. In vivo, DHLA attenuated osteophyte formation and cartilage degeneration induced by DMM surgery in OA model mice. Moreover, the upregulation of MMP13 and TXNIP was suppressed by DHLA, as well as the downregulation of Collagen II, GPX4, and FOXO1 in articular cartilage. DHLA inhibits chondrocytes ferroptosis to alleviate OA progression through the FOXO1/TXNIP signaling pathway, offering a potential treatment strategy for OA.